Facebook
Twitter
Telegram
Report an Errorimmatics biotechnologies GmbH Balance Sheet 2011-2024 | IMTXW
Annual Balance Sheet immatics biotechnologies GmbH
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 1.88 M | 1.41 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 208 M | 103 M | 39.4 M | 8.42 M | - | - | - | - | - | - |
Book Value |
- | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | 87.4 M | -40.8 M | -9.17 M | -2.26 M | - | - | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet immatics biotechnologies GmbH
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 14 M | - | 7.14 M | - | 4.74 M | - | 4.31 M | - | - | - | 1.82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 129 M | - | 55.4 M | - | 66.9 M | - | 89.8 M | - | - | - | 106 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | 161 M | - | 167 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -466 M | - | -538 M | - | -494 M | - | -444 M | - | - | - | -233 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | 368 M | - | 175 M | - | 217 M | - | 255 M | - | - | - | 134 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | 265 M | - | 133 M | - | 160 M | - | 208 M | - | 86.1 M | - | 103 M | - | - | - | 39.4 M | - | - | - | 8.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | 368 M | - | 175 M | - | 55.6 M | - | 87.4 M | - | - | - | 134 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | 125 M | - | 24.1 M | - | 55.6 M | - | 87.4 M | - | -68 M | - | -40.8 M | - | - | - | -9.17 M | - | - | - | -2.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency